🔗 Share this article

A shadow economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Investigational Drug Gaining Popularity Online

The experimental drug, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Followers are urged to contact these accounts directly for source information, while also obtaining discount codes.

Thriving Trade on Social Networks

Additionally, a flourishing market exists on messaging services, where groups with numerous of members share comparison images, administration instructions and claims of rapid British shipping. Sellers promote the substance there before directing customers to other platforms for transactions.

Understanding The Experimental Drug

This medication is an experimental injectable developed by US drugmaker Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.

Healthcare Professionals Voice Worries

Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could lead to users administering products of uncertain source.

Several professionals stated the popularity for retatrutide could be connected to the rising cost of approved slimming products such as Mounjaro.

Regulatory Status and Enforcement

Marketing retatrutide on TikTok or Telegram is prohibited in the UK, as it is an unapproved medication that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate medicines, advertising, and customer laws, potentially leading to penalties, legal action or imprisonment.

Platform Response and Material Removal

Based on TikTok, the platform has removed problematic content and prohibited associated keywords and search suggestions. The company said it was committed to maintaining the platform safe and allocating resources in enhancing compliance measures.

Digital Marketplace Operations

Research also found groups with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with thousands of users, populated with photos of slimming results, positive testimonials and detailed guides for preparing or injecting at home.

After moments of joining one community, a seller shared contact information, where most transactions take place. The seller provided an instruction manual and promised delivery within 48 hours. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None asked about weight, health issues or past usage.

Product Details and Pricing

Within these groups, messages display dark colored packages with Royal Mail labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors typically priced at 160 pounds for 20 milligrams. When asked how much time a injector should be used, vendors give contradictory answers varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A spokesperson for Telegram said it regularly moderated harmful material on its service including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they cannot confirm. Even if the science behind retatrutide is sound, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in interest to current price rises for approved slimming medications such as Mounjaro. “With prices rising, individuals are using online platforms. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her team has already encountered patients harmed by personal administration from unverified sources. “We understand the frustration, but purchasing from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Producer Statement

A spokesperson from the pharmaceutical company stated the substance was in third stage research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they explained, adding that any product “misleadingly claiming itself as a Lilly experimental product not yet approved … may subject patients to potentially serious health risks”.